KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,936,340 | -53.8% | 3,525,957 | 0.0% | 7.88% | +0.9% |
| Q2 2023 | $10,683,650 | -13.4% | 3,525,957 | +78.5% | 7.80% | -14.5% |
| Q1 2023 | $12,343,756 | +131.3% | 1,975,001 | +125.7% | 9.12% | +120.1% |
| Q4 2022 | $5,337,506 | -49.0% | 875,001 | 0.0% | 4.15% | -48.4% |
| Q3 2022 | $10,456,000 | -5.2% | 875,001 | 0.0% | 8.04% | +4.3% |
| Q2 2022 | $11,034,000 | +12.0% | 875,001 | 0.0% | 7.71% | +91.6% |
| Q1 2022 | $9,853,000 | -36.5% | 875,001 | 0.0% | 4.02% | +5.6% |
| Q4 2021 | $15,505,000 | -23.0% | 875,001 | 0.0% | 3.81% | -39.2% |
| Q3 2021 | $20,143,000 | -1.1% | 875,001 | 0.0% | 6.26% | -21.9% |
| Q2 2021 | $20,370,000 | -25.3% | 875,001 | 0.0% | 8.01% | -0.0% |
| Q1 2021 | $27,265,000 | -21.7% | 875,001 | 0.0% | 8.02% | -68.9% |
| Q4 2020 | $34,808,000 | – | 875,001 | – | 25.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |